Modified Chimeric superantigens and their use

Details Modified Chimeric superantigens and their use Modified Chimeric superantigens and their use

2007-06-05

2007-06-05

Ungar, Susan (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Reexamination Certificate

active

10283838

ABSTRACT:
A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, preferably TCRVβ, and T cell activation have been replaced by another amino acid residue while retaining the ability to activate a subset of T cells.In preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens.A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs.An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as pharmaceutical.

REFERENCES:
patent: 3627644 (1971-12-01), Okamoto et al.
patent: 4237224 (1980-12-01), Cohen et al.
patent: 4268434 (1981-05-01), Higerd et al.
patent: 4681870 (1987-07-01), Balint, Jr. et al.
patent: 4699783 (1987-10-01), Terman et al.
patent: 4980160 (1990-12-01), Goldberg et al.
patent: 5091091 (1992-02-01), Terman
patent: 5519114 (1996-05-01), Johnson et al.
patent: 5545716 (1996-08-01), Johnson et al.
patent: 5728388 (1998-03-01), Terman
patent: 5858363 (1999-01-01), Dohlsten et al.
patent: 5859207 (1999-01-01), Johnson et al.
patent: 6042837 (2000-03-01), Kalland et al.
patent: 6126945 (2000-10-01), Terman
patent: 6180097 (2001-01-01), Terman
patent: 6197299 (2001-03-01), Dohlsten et al.
patent: 6221351 (2001-04-01), Terman
patent: 6251385 (2001-06-01), Terman
patent: 6338845 (2002-01-01), Terman
patent: 6340461 (2002-01-01), Terman
patent: 6399332 (2002-06-01), Ulrich et al.
patent: 6447777 (2002-09-01), Terman et al.
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 6632441 (2003-10-01), Schlievert et al.
patent: 6632640 (2003-10-01), Lee et al.
patent: 6692746 (2004-02-01), Terman et al.
patent: 6713284 (2004-03-01), Ulrich et al.
patent: 2001/0046501 (2001-11-01), Johnson et al.
patent: 2002/0018781 (2002-02-01), Schlievert et al.
patent: 2002/0028211 (2002-03-01), Kaempfer et al.
patent: 2002/0039585 (2002-04-01), Schlievert et al.
patent: 2002/0051765 (2002-05-01), Terman
patent: 2002/0058032 (2002-05-01), Hirai et al.
patent: 2002/0086813 (2002-07-01), Schlievert et al.
patent: 2002/0115190 (2002-08-01), Chen
patent: 2002/0141981 (2002-10-01), Lawman et al.
patent: 2002/0177551 (2002-11-01), Terman
patent: 2003/0009015 (2003-01-01), Ulrich et al.
patent: 2003/0036644 (2003-02-01), Ulrich
patent: 2003/0039655 (2003-02-01), Forsberg et al.
patent: 2003/0092894 (2003-05-01), Antonsson et al.
patent: 2003/0124142 (2003-07-01), Fraser et al.
patent: 2003/0157113 (2003-08-01), Terman
patent: 2004/0142464 (2004-07-01), Lawman et al.
patent: 2828947 (1979-01-01), None
patent: 355047 (1990-02-01), None
patent: 9000592 (1991-08-01), None
patent: 9201470 (1993-11-01), None
patent: WO87/02602 (1987-05-01), None
patent: WO89/07947 (1989-09-01), None
patent: WO9100342 (1991-01-01), None
patent: WO91/04053 (1991-04-01), None
patent: WO91/10680 (1991-07-01), None
patent: WO92/01470 (1992-02-01), None
patent: WO93/01302 (1993-01-01), None
patent: WO93/14634 (1993-08-01), None
patent: WO93/24136 (1993-12-01), None
patent: WO96/01650 (1996-01-01), None
Kalland et al., 1993, Cell Biophysics 22:147-164.
Johnstone and Thorpe, 1997, Immunochemistry in Practice, Blackwell Scientific Publications (Oxford, England), pp. 49-50.
Gura et al., 1997, Science 278:1041-1042.
Burgess, 1990, J. Cell Biol. 111:2129-2138.
Lazar et al., 1988, Mol. Cell Biol. 8(3):1247-1252.
Bowie et al., 1990, 247:1306-1310.
U.S. Appl. No. 09/463,470, filed Jan. 21, 2000, Soegaard et al.
U.S. Appl. No. 09/463,470, filed Jan. 21, 2000.
Fraser, J.D., et al,; In: B.T. Huber, E. Palmer (eds) Current Communications in Cell and Molecular Biology 7. Cold Spring Harbour Laboratory Press, Cold Spring Harbor , NY; pp. 7-29.
Accolla, R.S.; Human B cell variants immunoselected against a single la antigen subset have lost expression of several la antigen subsets; J Exp Med. 157(3):1053-1058, Mar. 1, 1983.
Kavathas, P., et al.; Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells; Proc Natl Acad Sci USA. 77(7):4251-4255, Jul. 1980.
Abrahmsen, L., et al.; Characterization of two distinct MHC class II binding sites in the superantigenStaphylococcalenterotoxin A. EMBO 14:2978-2986, 1995.
Atonsson, P., et al.; (1996), ABRF '96: Biomolecular Techniques, Holiday Inn Golden Gateway, San Francisco, CA. Mar. 30-Apr. 2, 1996.
Dohlsten, et al.; Two subsets of human peripheral blood CD4+ T helper cells differing in the capacity to produce IL-2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J. Immunol. 18:1173-1178, 1988.
Dohlsten, M., et al.; Monoclonal antibody-targeted superantigens: A different class of anti-tumor agents. Proc. Natl. Acad. Sci. USA 88:9287-9291, 1991.
Dohlsten, M., et al.; Monoclonal antibody-superantigen fusion proteins: Tumor specific agents for T cell based tumor therapy. Proc. Natl. Acad. Sci. USA 91:8945-8949, 1994.
Fleury, S., et al.; Mutational analysis of the interaction between CD4 and class II MHC: class II antigens. Cell 66:1037-1049, 1991.
Grossman, et al.; Mutation of the disulfide loop inStaphylococcalenterotoxin A. Consequences for T cell recognition. J. Immunol. 147:3274-3281, (1991).
Hartwig, U.F., et al.; Mutations affecting MHC class II binding of the superantigenStreptococcalerythrogenic toxin A. Int. Immunol. 5(8):869-875, Aug. 1993.
Holzer, U. et al.; Superantigen-Staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells; Cancer Immunol. Immunother. 41(2):126-136, 1995.
Horton, R.M. et al.; Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction; Biotechniques 8:528-535, 1990.
Hudson, K.R., et al.; Two adjacent residues inStaphylococcalenterotoxins A and E determine T cell receptor V beta specificity; J Exp Med. 177(1):175-184, Jan. 1, 1993.
Hufnagle, W.O., et al.; The carboxyl-terminal region ofStaphylococcalenterotoxin type A is required for a fully active molecule. Infect Immun 59:2126-2134, 1991.
Ihle J, et al.; Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines; Cancer Res. 55(3):623-628, Feb. 1, 1995.
Irwin, M.J., et al.; Entertoxin residues determining T-cell receptor Vb binding specificity. Nature 359:841-843, 1992.
Kappler, J.W., et al.; Mutations defining functional regions of the superantigenStaphylococcalenterotoxin B. J Exp Med 175:387-396, 1992.
Kotzin, B.L., et al.; Superantigens and their potential role in human disease; Adv Immunol 54:99-166, 1993.
Kraulis, P.J.; MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures; J Appl Cryst 24:946-950, 1991.
Lamphear J.G., et al.; Residues near the amino and carboxyl termini ofStaphylococcalenterotoxin E independently mediate TCR V beta-sepcific interactions; J Immunol. 156(6):2178-2185, Mar. 15, 1996.
Lando, P.A., et al.; Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity; Immunology 80:236-241, 1993.
Mollick, J.A., et al.; Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity. J Exp Med 177:283-293, 1993.
Newell K.A., et al.; In vivo T-cell activation byStaphylococcalenterotoxin B prevents outgrowth of a malignant tumor; Proc Natl Acad Sci U S A. 88(3):1074-1078, Feb. 1, 1991.
Schad, E.M., et al.; Crystal structure of the superantigen,Staphylococcalenterotoxin type A; EMBO J. 14:3292-3301, 1995.
Von Heijne, G.; A new method for predicting signal sequence cleavage sites. Nucleic Acid Res. 14:1483-1490, 1986.
Letter of Aug. 27, 1998 to European P

Affiliated with

Also associated with

Rating

Modified Chimeric superantigens and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified Chimeric superantigens and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Chimeric superantigens and their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3836611